Key facts
- Hepta Medical’s last known valuation is $1.1M (Sep 2022).
- It has raised $12.3M; the latest was Later Stage VC ($11.6M) in Mar 2026.
- Notable investors include Bpifrance, MedTech Innovator, UI Investissement, Sofinnova Partners, Supernova Invest — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Hepta Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Hepta Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hepta Medical
Developer of a flexible microwave ablation platform designed to introduce minimally invasive nonsurgical treatment for early lung cancer. The company's technology develops an ablation catheter with integrated tissue temperature sensing to allow for real-time monitoring of tissue ablation, enabling healthcare professionals to ablate while controlling the size of the lesion, resulting in more efficient and safer outcomes for patients.
- Sector
- Healthcare
- HQ
- Suresnes, France
- Founded
- 2017
- Employees
- 9
- Website
- heptamed.com/
- Ownership
- Privately Held (backing)
Hepta Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hepta Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hepta Medical in its N-PORT filings yet. We sweep new filings monthly.